185 related articles for article (PubMed ID: 15776284)
1. Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system.
Weber F; Byrne SN; Le S; Brown DA; Breit SN; Scolyer RA; Halliday GM
Cancer Immunol Immunother; 2005 Sep; 54(9):898-906. PubMed ID: 15776284
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin.
Halliday GM; Le S
Int Immunol; 2001 Sep; 13(9):1147-54. PubMed ID: 11526095
[TBL] [Abstract][Full Text] [Related]
3. Progressor but not regressor skin tumours inhibit Langerhans' cell migration from epidermis to local lymph nodes.
Lucas AD; Halliday GM
Immunology; 1999 May; 97(1):130-7. PubMed ID: 10447724
[TBL] [Abstract][Full Text] [Related]
4. TGFbeta is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction.
Byrne SN; Knox MC; Halliday GM
Immunol Cell Biol; 2008 Jan; 86(1):92-7. PubMed ID: 17768418
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis.
Imai K; Minamiya Y; Koyota S; Ito M; Saito H; Sato Y; Motoyama S; Sugiyama T; Ogawa J
J Exp Clin Cancer Res; 2012 Jan; 31(1):3. PubMed ID: 22233831
[TBL] [Abstract][Full Text] [Related]
6. In vitro treatment of human transforming growth factor-beta1-treated monocyte-derived dendritic cells with haptens can induce the phenotypic and functional changes similar to epidermal Langerhans cells in the initiation phase of allergic contact sensitivity reaction.
Aiba S; Manome H; Yoshino Y; Tagami H
Immunology; 2000 Sep; 101(1):68-75. PubMed ID: 11012755
[TBL] [Abstract][Full Text] [Related]
7. High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress.
Byrne SN; Halliday GM
Cancer Immunol Immunother; 2003 Jun; 52(6):396-402. PubMed ID: 12739069
[TBL] [Abstract][Full Text] [Related]
8. Retroviral delivery of transforming growth factor-beta1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival.
Takayama T; Kaneko K; Morelli AE; Li W; Tahara H; Thomson AW
Transplantation; 2002 Jul; 74(1):112-9. PubMed ID: 12134108
[TBL] [Abstract][Full Text] [Related]
9. The roles of antigen-specificity, responsiveness to transforming growth factor-β and antigen-presenting cell subsets in tumour-induced expansion of regulatory T cells.
Coe D; Addey C; White M; Simpson E; Dyson J; Chai JG
Immunology; 2010 Dec; 131(4):556-69. PubMed ID: 20722761
[TBL] [Abstract][Full Text] [Related]
10. [In vivo migration and survival of donor-derived dendritic cell progenitors genetically modified using an adenoviral vector encoding cDNA for TGF beta 1].
Zhong C; Li WZ; Lü L
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):174-7. PubMed ID: 11601033
[TBL] [Abstract][Full Text] [Related]
11. Phagocytosis by dendritic cells rather than MHC IIhigh macrophages is associated with skin tumour regression.
Byrne SN; Halliday GM
Int J Cancer; 2003 Sep; 106(5):736-44. PubMed ID: 12866034
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.
Harimoto H; Shimizu M; Nakagawa Y; Nakatsuka K; Wakabayashi A; Sakamoto C; Takahashi H
Immunol Cell Biol; 2013 Oct; 91(9):545-55. PubMed ID: 24018532
[TBL] [Abstract][Full Text] [Related]
13. Modulation of CD11c+ lung dendritic cells in respect to TGF-β in experimental pulmonary fibrosis.
Chakraborty K; Chatterjee S; Bhattacharyya A
Cell Biol Int; 2017 Sep; 41(9):991-1000. PubMed ID: 28557137
[TBL] [Abstract][Full Text] [Related]
14. Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration.
Huang A; Gilmour JW; Imami N; Amjadi P; Henderson DC; Allen-Mersh TG
Clin Exp Immunol; 2003 Nov; 134(2):270-8. PubMed ID: 14616787
[TBL] [Abstract][Full Text] [Related]
15. TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression.
Nakamura S; Yaguchi T; Kawamura N; Kobayashi A; Sakurai T; Higuchi H; Takaishi H; Hibi T; Kawakami Y
J Immunother; 2014; 37(2):63-72. PubMed ID: 24509168
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
Kobie JJ; Wu RS; Kurt RA; Lou S; Adelman MK; Whitesell LJ; Ramanathapuram LV; Arteaga CL; Akporiaye ET
Cancer Res; 2003 Apr; 63(8):1860-4. PubMed ID: 12702574
[TBL] [Abstract][Full Text] [Related]
17. The alpha 1 beta 1 and alpha E beta 7 integrins define a subset of dendritic cells in peripheral lymph nodes with unique adhesive and antigen uptake properties.
Pribila JT; Itano AA; Mueller KL; Shimizu Y
J Immunol; 2004 Jan; 172(1):282-91. PubMed ID: 14688336
[TBL] [Abstract][Full Text] [Related]
18. Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta.
Lee WC; Zhong C; Qian S; Wan Y; Gauldie J; Mi Z; Robbins PD; Thomson AW; Lu L
Transplantation; 1998 Dec; 66(12):1810-7. PubMed ID: 9884280
[TBL] [Abstract][Full Text] [Related]
19. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.
Ahn YH; Hong SO; Kim JH; Noh KH; Song KH; Lee YH; Jeon JH; Kim DW; Seo JH; Kim TW
Clin Exp Immunol; 2015 Jul; 181(1):164-78. PubMed ID: 25753156
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-β1 impairs lymph node homing of dendritic cells by downregulating C-type lectin receptor-2 expression.
Gujar R; Sen P
Cytokine; 2018 Oct; 110():39-43. PubMed ID: 29702464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
